Teva introduces generic Provigil

Download PDF Copy

Editorial Checklist

Reviewed

TevaMar 31 2012

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announces the launch of the authorized generic of Provigil® (modafinil). Provigil® is marketed by Cephalon, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. This product will continue to be manufactured under the brand product's new drug application at the same facility where it is currently produced. Shipping of the product has commenced.

The brand product had annual sales of approximately $1.1 billion in the United States, based on IMS sales data.

Source:

Posted in: Pharmaceutical News

Tags: Biotechnology, Generic Drug, Medicaid, Medicare, New Drug Application, Oncology, Pain, Pharmaceuticals, Protonix

Comments (0)

Download PDF Copy

Suggested Reading

Annona squamosa extracts show promise in treating pain and arthritis

Annona squamosa extracts show promise in treating pain and arthritis

Research from second pig heart transplant provides new directions for xenotransplantation

Research from second pig heart transplant provides new directions for xenotransplantation

New modular strategy reduces piperidine synthesis steps for pharmaceuticals

New modular strategy reduces piperidine synthesis steps for pharmaceuticals

New study reveals complex attitudes toward psychedelic therapy

New study reveals complex attitudes toward psychedelic therapy

Danish studies find increased risk of optic nerve damage with diabetes medicine

Danish studies find increased risk of optic nerve damage with diabetes medicine

Study reveals how fatty liver disease leads to liver cancer

Study reveals how fatty liver disease leads to liver cancer

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Breakthrough pig kidney transplant ends dialysis for Alabama woman

Breakthrough pig kidney transplant ends dialysis for Alabama woman

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Carrots may offer natural support for people with type 2 diabetes